57 completed, 3 unknown, 2 withdrawn, 1 recruiting. 23 Phase 3, 20 Phase 2, 8 Phase 4, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 23 |
| Phase 2 | 20 | Completed 20 |
| Phase 4 | 8 | Completed 8 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Meningococcal Disease: new trials by email Literature Review of Meningococcal Disease trials Research Report on Meningococcal Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety of PENBRAYA During Pregnancy PENBRAYA - Meningococcal Disease | Recruiting | Pfizer | 50 | 2024-05-03 | 2026-08-17 | |
| Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT) Licenced 4CMenB Vaccine - Gonorrhea, Meningococcal Disease | Unknown | University of Adelaide | 7100 | 2021-03-04 | 2023-03-09 | |
| Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study Serum Bactericidal Assays - HIV/AIDS, Meningococcal Disease | Unknown | St George's, University of London | 55 | 2020-11-26 | 2022-02-02 | |
| Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays Cord blood sampling - Pertussis, Meningococcal Disease | Unknown | St George's, University of London | 45 | 2020-10-28 | 2021-01-12 | |
| Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA. Meningitis, Meningococcal, Meningococcal Sepsis | Completed | Belfast Health and Social Care Trust | 1329 | 2017-11-09 | 2019-12-12 | |
| Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B 4CMenB Vaccine - Prematurity, Vaccination | Phase 4 | Completed | St George's, University of London | 136 | 2017-08-01 | 2020-12-01 |
| South Australian Meningococcal B Vaccine Herd Immunity Study Licensed 4CMenB vaccine - Meningococcal Disease | Phase 4 | Completed | University of Adelaide | 34489 | 2017-04-01 | 2019-07-02 |
| PRIME Follow up - Quadri Meningo Vacinees venepuncture only - Meningococcal Disease | Completed | Public Health England | 57 | 2016-12-01 | 2020-03-03 | |
| A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) MenABCWY+OMV vaccine - Meningococcal Disease, Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 129 | 2015-06-30 | 2020-07-09 |
| Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents Meningococcal ABCWY, Placebo - Meningococcal Disease | Phase 2 | Completed | GlaxoSmithKline | 189 | 2014-12-01 | 2018-09-24 |
| Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study Meningococcal quadrivalent CRM-197 conjugate vaccine - Meningococcal Disease, Infections, Meningococcal | Completed | GlaxoSmithKline | 144 | 2014-12-01 | 2019-10-21 | |
| Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry Meningococcal quadrivalent CRM-197 conjugate vaccine - Meningococcal Disease, Pregnancy | Completed | GlaxoSmithKline | 93 | 2014-09-30 | 2019-06-21 | |
| Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. Bexsero®, Routine vaccines - Meningococcal Disease, Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 225 | 2014-09-11 | 2020-08-25 |
| Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents MenABCWY, Placebo, MenACWY - Meningococcal Disease | Phase 2 | Completed | Novartis Vaccines | 305 | 2014-05-01 | 2018-09-12 |
| Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. rMenB+OMV - Meningococcal Disease | Phase 3 | Completed | Novartis | 239 | 2014-05-01 | 2017-02-15 |
| Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180) MenABCWY+OMV, MenABCWY+¼OMV, Placebo - Meningococcal Disease | Phase 2 | Completed | Novartis Vaccines | 194 | 2013-12-01 | 2016-10-25 |
| Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. Meningococcal B Recombinant vaccine rMenB+OMV NZ, Placebo, Meningococcal ACWY-CRM conjugate vaccine - Meningococcal Disease | Phase 3 | Completed | Novartis Vaccines | 264 | 2013-11-01 | 2015-10-30 |
| Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers MenACWY-CRM, MenACWY-TT - Meningococcal Disease | Phase 2 | Completed | Novartis Vaccines | 202 | 2013-11-01 | 2015-11-04 |
| Hepatitis B Vaccination in Infants Menjugate, Menitorix, NeisVac-C - Meningococcal Disease, Pneumococcal Disease | Phase 4 | Completed | Public Health England | 300 | 2013-07-01 | 2020-10-01 |
| Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine - Meningococcal Disease | Phase 4 | Completed | Novartis Vaccines | 465 | 2013-05-01 | 2014-08-15 |
Showing 20 of 63. Sign in to see all of them.
Meningococcal Infections (63) · Meningitis (21) · Meningitis, Meningococcal (19) · Whooping Cough (3) · Hepatitis B (2) · Premature Birth (2) · Acquired Immunodeficiency Syndrome (1) · Diphtheria (1) · Encephalitis, Japanese (1) · Gonorrhea (1) · Hepatitis A (1) · Hereditary Complement Deficiency Diseases (1) · Influenza, Human (1) · Pneumococcal Infections (1) · Rabies (1)
Bacterial Infections (63) · Bacterial Infections and Mycoses (63) · Gram-Negative Bacterial Infections (63) · Infections (63) · Neisseriaceae Infections (63) · Nervous System Diseases (32) · Neuroinflammatory Diseases (32) · Central Nervous System Bacterial Infections (19) · Central Nervous System Diseases (19) · Central Nervous System Infections (19) · Meningitis, Bacterial (19) · Meningitis (11) · Virus Diseases (5) · Communicable Diseases (4) · RNA Virus Infections (4)
MenACWY-CRM vaccine (11) · 4CMenB vaccine (7) · Meningococcal Vaccines (7) · Tetanus Toxoid (3) · Hepatitis B Vaccines (2) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Measles-Mumps-Rubella Vaccine (2) · Rubella Vaccine (2) · diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine (2) · 13-valent pneumococcal vaccine (1) · Cordocentesis (1) · Engerix-B (1) · Hematologic Tests (1) · Japanese Encephalitis Vaccines (1) · MenACWY (1)
Novartis Vaccines (34) · GlaxoSmithKline (7) · Sanofi Pasteur, a Sanofi Company (5) · Novartis (4) · St George's, University of London (3) · Public Health England (2) · University of Adelaide (2) · Belfast Health and Social Care Trust (1) · Leiden University Medical Center (1) · London School of Hygiene and Tropical Medicine (1) · Pfizer (1) · University of California, Los Angeles (1) · University of Oxford (1)
United States (17) · United Kingdom (14) · Italy (8) · Chile (5) · Czechia (5) · Germany (5) · Australia (4) · Canada (4) · South Korea (4) · Spain (4) · Colombia (3) · Panama (3) · Poland (3) · Finland (2) · Russia (2)
Elizabeth Coates, PhD (2) · Andrew J Pollard, BA, MBBS, FRCPCH, PhD (1) · Anna Calvert, MBChB (1) · Brian Greenwood, MD (1) · Helen Marshall (1) · James Stuart, MD (1) · Leo Visser, MD, PhD (1) · MIchael D Shields (1)
PMID 33020485, PMID 35257644, PMID 21177912, PMID 30061029, PMID 19895922, PMID 20164251, PMID 20844462, PMID 22260988, PMID 22394992, PMID 23114372, PMID 23324563, PMID 23566945, PMID 23958808, PMID 24062178, PMID 24873986, PMID 25308927, PMID 25483566, PMID 25748976, PMID 25802309, PMID 25969894, PMID 26135245, PMID 26232542, PMID 26398741, PMID 26479973, PMID 26756390, PMID 26826544, PMID 28318767, PMID 28719502, PMID 28941623, PMID 29038320, PMID 29253560, PMID 29550195, PMID 29778515, PMID 30060751, PMID 30068713, PMID 31110098, PMID 31175126, PMID 31327652, PMID 31634044, PMID 31971677, PMID 32447370, PMID 32586928, PMID 32712083, PMID 33087092, PMID 33186517, PMID 33325757, PMID 33587122, PMID 35214767, PMID 38234190, PMID 38977298
2005 (1), 2008 (1), 2009 (1), 2014 (1), 2016 (1), 2017 (1)